dr. rizvi on the utility of trastuzumab deruxtecan in nsclc
Published 3 years ago • 113 plays • Length 0:56Download video MP4
Download video MP3
Similar videos
-
1:29
dr. rizvi on utilizing molecular characteristics to inform treatment decisions in nsclc
-
1:13
dr. hamilton on the efficacy of trastuzumab deruxtecan in her2-low breast cancer
-
1:26
dr. rizvi on activity and toxicity of pembrolizumab for nsclc
-
1:03
dr. rizvi discusses pembrolizumab for non-small cell lung cancer
-
0:50
dr. rizvi on pseudoprogression in lung cancer after immunotherapy
-
1:15
dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
-
1:00
dr. rizvi on pseudoprogression in lung cancer after immunotherapy
-
1:16
dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
-
48:15
immunotherapy for lung cancer: pd-1 and beyond, with naiyer rizvi
-
1:17
dr. o’regan on the utility of cdk4/6 inhibitors in breast cancer
-
6:24
the initial approach to sclc treatment tbr
-
6:22
diagnosis and treatment of small cell lung cancer
-
1:39
dr. rizvi on the echelon-1 trial follow-up in hodgkin lymphoma
-
1:45
strategies to target her2 in lung cancer
-
12:12
breast cancer treatment - trastuzumab biosimilars
-
1:05
dr. hamilton on the optimal duration of trastuzumab in her2 breast cancer
-
0:59
dr. hope rugo on safety of trastuzumab biosimilar for her2 breast cancer
-
1:30
dr. hope rugo on trastuzumab biosimilar in her2-positive breast cancer
-
1:35
dr. drilon on activity of larotrectinib in trk fusion–positive nsclc